Literature DB >> 18829752

Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses.

Courtney Dow1, Carla Oseroff, Bjoern Peters, Courtney Nance-Sotelo, John Sidney, Michael Buchmeier, Alessandro Sette, Bianca R Mothé.   

Abstract

Activation of CD4(+) T cells helps establish and sustain other immune responses. We have previously shown that responses against a broad set of nine CD4(+) T-cell epitopes were present in the setting of lymphocytic choriomeningitis virus (LCMV) Armstrong infection in the context of H-2(d). This is quite disparate to the H-2(b) setting, where only two epitopes have been identified. We were interested in determining whether a broad set of responses was unique to H-2(d) or whether additional CD4(+) T-cell epitopes could be identified in the setting of the H-2(b) background. To pursue this question, we infected C57BL/6 mice with LCMV Armstrong and determined the repertoire of CD4(+) T-cell responses using overlapping 15-mer peptides corresponding to the LCMV Armstrong sequence. We confirmed positive responses by intracellular cytokine staining and major histocompatibility complex (MHC)-peptide binding assays. A broad repertoire of responses was identified, consisting of six epitopes. These epitopes originate from the nucleoprotein (NP) and glycoprotein (GP). Out of the six newly identified CD4(+) epitopes, four of them also stimulate CD8(+) T cells in a statistically significant manner. Furthermore, we assessed these CD4(+) T-cell responses during the memory phase of LCMV Armstrong infection and after infection with a chronic strain of LCMV and determined that a subset of the responses could be detected under these different conditions. This is the first example of a broad repertoire of shared epitopes between CD4(+) and CD8(+) T cells in the context of viral infection. These findings demonstrate that immunodominance is a complex phenomenon in the context of helper responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829752      PMCID: PMC2583689          DOI: 10.1128/JVI.00435-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Defining parameters for successful immunocytotherapy of persistent viral infection.

Authors:  D P Berger; D Homann; M B Oldstone
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

2.  Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes.

Authors:  J E Gairin; H Mazarguil; D Hudrisier; M B Oldstone
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection.

Authors:  A Oxenius; R M Zinkernagel; H Hengartner
Journal:  Immunity       Date:  1998-10       Impact factor: 31.745

4.  Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.

Authors:  A Oxenius; M F Bachmann; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

5.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells.

Authors:  D Moskophidis; F Lechner; H Pircher; R M Zinkernagel
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

6.  Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice.

Authors:  R G van der Most; K Murali-Krishna; J L Whitton; C Oseroff; J Alexander; S Southwood; J Sidney; R W Chesnut; A Sette; R Ahmed
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

7.  Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.

Authors:  R D Cardin; J W Brooks; S R Sarawar; P C Doherty
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

8.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells.

Authors:  A Gallimore; J Hombach; T Dumrese; H G Rammensee; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

10.  Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.

Authors:  A Oxenius; M F Bachmann; P G Ashton-Rickardt; S Tonegawa; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

View more
  25 in total

Review 1.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

2.  STAT5 is critical to maintain effector CD8+ T cell responses.

Authors:  Pulak Tripathi; Sema Kurtulus; Sara Wojciechowski; Allyson Sholl; Kasper Hoebe; Suzanne C Morris; Fred D Finkelman; H Leighton Grimes; David A Hildeman
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

3.  CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination.

Authors:  Lauren E Yauch; Tyler R Prestwood; Monica M May; Malika M Morar; Raphaël M Zellweger; Bjoern Peters; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

4.  CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.

Authors:  Allison F Christiaansen; Upasna Gaur Dixit; Rhea N Coler; Anna Marie Beckmann; Steven G Reed; Patricia L Winokur; M Bridget Zimmerman; Steven M Varga; Mary E Wilson
Journal:  Vaccine       Date:  2017-06-27       Impact factor: 3.641

5.  Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.

Authors:  Mitra Bhattacharyya; Patrick Madden; Nathan Henning; Shana Gregory; Malika Aid; Amanda J Martinot; Dan H Barouch; Pablo Penaloza-MacMaster
Journal:  Immunology       Date:  2017-07-14       Impact factor: 7.397

6.  Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Authors:  Joshua M Walker; Hans-Peter Raué; Mark K Slifka
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

7.  Induction of a cross-reactive CD8(+) T cell response following foot-and-mouth disease virus vaccination.

Authors:  Efrain Guzman; Geraldine Taylor; Bryan Charleston; Shirley A Ellis
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

8.  Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think.

Authors:  Daniel S McDermott; Steven M Varga
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

9.  MHC class I and II peptide homology regulates the cellular immune response.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Jonathan Vazquez-Perez; Colby J Hofferek; Scott A Weldon; Yunyu Baig; Indira Vedula; Jonathan M Levitt; William K Decker
Journal:  FASEB J       Date:  2020-04-16       Impact factor: 5.191

10.  Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage.

Authors:  Maya F Kotturi; Jason Botten; Matt Maybeno; John Sidney; Jean Glenn; Huynh-Hoa Bui; Carla Oseroff; Shane Crotty; Bjoern Peters; Howard Grey; Daniel M Altmann; Michael J Buchmeier; Alessandro Sette
Journal:  Immunome Res       Date:  2010-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.